Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKCrj with MDRI, MRP and LRP gene expression
1998

Differences in Gene Expression in Breast Cancer Stages

Sample size: 64 publication Evidence: moderate

Author Information

Author(s): J Beck, B Bohnet, D Brugger, P Bader, J Dietl, RJ Scheper, R Kandolf, C Liu, D Niethammer, V Gekeler

Primary Institution: Children's Hospital, University of Tubingen, Germany

Hypothesis

PKC could represent a key regulatory factor for up-regulation of various MDR-associated genes in response to chemotherapy.

Conclusion

The study found significant differences in gene expression between G2 and G3 breast cancers, suggesting that G3 tumors may respond better to chemotherapy due to lower expression levels of certain resistance genes.

Supporting Evidence

  • Significantly enhanced mean values for MRP, LRP and PKC gene expression were found in G2 tumors compared with G3.
  • Significant positive correlations between MDR1, MRP or LRP gene expression levels and PKC were determined.
  • The study suggests that the expression levels of certain genes may influence the effectiveness of chemotherapy in breast cancer.

Takeaway

This study looked at breast cancer samples and found that some genes related to drug resistance are expressed differently in tumors that are more or less aggressive.

Methodology

The study analyzed gene expression levels in tumor specimens from 64 patients using a cDNA-PCR approach.

Limitations

The observation period after the date of primary diagnosis is still too short to draw definitive conclusions about treatment outcomes.

Participant Demographics

Median age of participants was 58 years, ranging from 37 to 88 years; 35 patients had positive node status.

Statistical Information

P-Value

P < 0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication